Very conservative estimates.
Reality is there isn’t anything apart from corticosteroids outside of 13% of DMD boys in the US who can use Exondys51.
If we partner with Big Pharma, the distribution channels, clinical connections and capability to scale are tremendous.
Hence the modeling will be updated as soon as partnership is announced.
I think Morgan’s were modeling well above 30% market penetration.
I can’t see ANP going alone to market, to launch pharmaceutical products. Just not set up to do that…never will be.
.
Where others have failed will Atl1102 succeed ?, page-453
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.3¢ |
Change
-0.002(2.67%) |
Mkt cap ! $65.81M | |||
| Open | High | Low | Value | Volume |
| 7.5¢ | 7.5¢ | 7.3¢ | $31.44K | 421.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 661162 | 7.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 120000 | 1 |
View Market Depth
| Last trade - 15.59pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.4¢ |
Change
-0.002 ( 1.33 %) |
||||
| Open | High | Low | Volume | ||
| 7.4¢ | 7.4¢ | 7.4¢ | 14050 | ||
| Last updated 14.59pm 23/05/2024 ? | |||||
| PER (ASX) Chart |